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Abstract
Background: Hydroxyurea (HU) is the first approved pharmacological treatment of sickle cell anemia (SCA). The
objectives of this study were to develop population pharmacokinetic(PK)-pharmacodynamic(PD) models for HU in
order to characterize the exposure-efficacy relationships and their variability, compare two dosing regimens by
simulations and develop some recommendations for monitoring the treatment.
Methods: The models were built using population modelling software NONMEM VII based on data from two
clinical studies of SCA adult patients receiving 500-2000 mg of HU once daily. Fetal hemoglobin percentage (HbF
%) and mean corpuscular volume (MCV) were used as biomarkers for response. A sequential modelling approach
was applied. Models were evaluated using simulation-based techniques. Comparisons of two dosing regimens
were performed by simulating 10000 patients in each arm during 12 months.
Results: The PK profiles were described by a bicompartmental model. The median (and interindividual coefficient
of variation (CV)) of clearance was 11.6 L/h (30%), the central volume was 45.3 L (35%). PK steady-state was
reached in about 35 days. For a given dosing regimen, HU exposure varied approximately fivefold among patients.
The dynamics of HbF% and MCV were described by turnover models with inhibition of elimination of response. In
the studied range of drug exposures, the effect of HU on HbF% was at its maximum (median Imax was 0.57, CV
was 27%); the effect on MCV was close to its maximum, with median value of 0.14 and CV of 49%. Simulations
showed that 95% of the steady-state levels of HbF% and MCV need 26 months and 3 months to be reached,
respectively. The CV of the steady-state value of HbF% was about 7 times larger than that of MCV. Simulations with
two different dosing regimens showed that continuous dosing led to a stronger HbF% increase in some patients.
Conclusions: The high variability of response to HU was related in part to pharmacokinetics and to
pharmacodynamics. The steady-state value of MCV at month 3 is not predictive of the HbF% value at month 26.
Hence, HbF% level may be a better biomarker for monitoring HU treatment. Continuous dosing might be more
advantageous in terms of HbF% for patients who have a strong response to HU.
Trial Registration: The clinical studies whose data are analysed and reported in this work were not required to be
registered in France at their time. Both studies were approved by local ethics committees (of Mondor Hospital and
of Kremlin-Bicetre Hospital) and written informed consent was obtained from each patient.
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Sickle cell anemia.
Definition
Sickle cell anemia is an autosomal recessive genetic
blood disorder, caused by a mutation in the hemoglobin
gene and characterized by rigid sickle-shaped red blood
cells. Sickling decreases the cells’ elasticity and leads to
vaso-occlusion which may result in various complica-
tions, such as acute painful crises, ischemia and damage
of various organs, acute chest syndrome or stroke.
Background
The antineoplastic agent hydroxyurea (hydroxycarba-
mide) (HU) is the first approved pharmacological treat-
ment of sickle cell anemia (SCA). It inhibits the
production of the hemoglobin S that causes SCA and
favors the reactivation of fetal hemoglobin (HbF) expres-
sion [1]. In fact, a variety of mechanisms are believed to
be involved in HU beneficial effects in SCA, including
increased HbF synthesis by erythroid regeneration, NO-
related increases in soluble guanylate cyclase activity
and cyclic guanidine monophosphate (cGMP) that sti-
mulate HBG expression [2]. Other mechanisms may be
myelosuppression with a reduction of circulating neu-
trophils, increased erythrocyte water content, modified
erythrocyte endothelial cell interactions and altered vas-
cular tone by increasing NO bioavailability [3]. Recently,
Bartolucci et al. reported that HU could reduce abnor-
mal sickle cell adhesion to the vascular wall by regulat-
ing the activation state of adhesion molecules [4]. HU
treatment reduces the rate and severity of painful
attacks [5] and was shown to possibly increase survival
time [6].
The usual dosing of this oral treatment is daily doses
of 15-35 mg/kg (or less if there is renal insufficiency)
[7]. The most adequate individual dose is determined by
starting with 15 mg/kg and monitoring full blood cell
counts every two weeks. If after twelve weeks no cytope-
nia has developed, the dose is increased by 5 mg/kg.
Once their maximal tolerable dose is determined, the
patient can continue the treatment life-long, if no ser-
ious toxicities manifest or other issues arise.
D e s p i t et h ew i d e s p r e a du s eo fH U ,o n l yaf e ws t u d i e s
have been reported in the literature, especially concern-
ing its use in the indication of SCA. Little is known
about the relationship between drug exposure and effi-
cacy, evaluated by fetal hemoglobin (HbF) and mean
corpuscular volume (MCV) measurements. Although a
number of genetic polymorphisms have been found to
be associated with response to HU [8-10], the variability
of this response remains poorly characterized. The opti-
mal dosing schedule, the best strategy for monitoring
and adjusting the treatment, and the impact that may
have the prior determination of candidate genotypes on
HU dosing remain open to discussion. Part of these
questions may be addressed through simulations from
pharmacokinetic (PK) and pharmacodynamic (PD) mod-
els of HU. Therefore, this study aimed to develop popu-
lation PK-PD models for HU in order to characterize
the exposure-efficacy relationships and their variability.
These models were then used (1) to compare two dos-
ing regimens (one continuous daily and the other with
interruptions of 2 days after every 5 days) by simulation,
and (2) to develop some recommendations for monitor-
ing the treatment.
Methods
Two datasets from two studies with different designs
were used in this analysis: one from a PK-PD study with
up to 9 samples taken per patient over a period of up to
30 months, and the other from a PK study with 10 sam-
ples per patient taken over 24 hours after drug
administration.
PKPD study design (sparse sampling)
Study design and patient population
This 30-month, open-label, noncomparative, prospec-
tive, observational study was conducted in 81 adult
patients with sickle cell anemia at the Centre de référ-
ence pour les syndromes drépanocytaires majeurs,A P -
HP, GH H. Mondor, Université Paris Est-Créteil,F r a n c e
from 2007 to 2010. It focused on the benefits and risks
of HU, in particular the side effects in the short and
medium term, as well as the need for regular hematolo-
gical monitoring. The protocol was approved by the
local ethics committee of Mondor hospital, and written
informed consent was obtained from each patient. The
recruited SCA patients were of 18 years or older and
with Hb genotype HbSS (homozygous sickle Hb). In all
patients, SCA diagnosis was documented by standard
methods [7]. Patients who received erythropoietin or a
blood transfusion at a time that can interfere with the
results were excluded.
Treatment
HU treatment was started at a dose of 20 mg/kg orally
unless there was renal insufficiency (in this case it
started at 10 and 15 mg/kg). Since hematotoxicity is the
dose-limiting toxicity, the hematologic control was per-
formed every 15 days during the first month and then
every month; if needed, doses were adjusted to maintain
neutrophil counts higher than 3 × 10
9/L. In most cases,
the final dose of HU did not exceed 30 mg/kg.
Pharmacokinetics protocol
Blood was drawn from most patients on day 0 (D0),
D15, after 1 month (M1), M2, M4 and M6, as well as at
various later timepoints more sparsely (up to M30). It
was collected in heparinized tubes and centrifuged at
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plasma. The plasma was then stored at -20°C until the
samples were assayed. Plasma samples were assayed
using high performance liquid chromatography (HPLC)
coupled with UV-detection at 449 nm [11]. The analyti-
cal method was linear between 5 to 1000 μM, precise
(coefficients of variation ranging from 1.7 to 9.9%),
accurate (97.7 to 103.9%). The limit of quantification
(LOQ) was 7 μM (0.532 mg/L).
The following biologic variables were measured during
this study: creatinine, urea, lactate dehydrogenase
(LDH), hemoglobin (Hb), fetal hemoglobin (HbF), mean
corpuscular volume (MCV), mean corpuscular hemoglo-
bin (MCH), ferritin, bilirubin, aspartate transaminase
(AST), alanine transaminase (ALT), neutrophils (PMN)
and platelets. Body weight, age and sex data were also
documented.
PK study design (rich sampling)
These rich PK data come from a bioequivalence study of
standard hydroxyurea capsules and a new formulation of
1000 mg coated breakable tablets in adults with homo-
zygous SCA or S/b-thalassemia. The complete study
protocol is given in a publication of the noncompart-
mental analysis of the PK data [12]. The assay validation
p a r a m e t e r sw e r et h es a m ea sf o rt h es p a r s eP Kd a t a
study [11].
These data contain 10 blood samples per patient, from
16 patients who took hydroxyurea doses ranging from
1000 mg to 2000 mg. The samples were taken at base-
l i n ea n d4 5 ,9 0 ,1 2 0 ,1 5 0 ,1 8 0 ,2 4 0 ,3 6 0 ,4 8 0m i n u t e s
after HU administration at the study center, as well as
trough samples after 24 hours.
Population PK-PD models
Population analyses were performed using NONMEM
software (version VII) [13]. PK model parameters were
estimated using the second order conditional estimation
(Laplacian) method with interaction between interindivi-
dual and residual variabilities. This estimation method is
more accurate than the standard first order conditional
estimation (FOCE) method. In this PK analysis it was
needed to correctly handle the concentrations below the
limit of quantification (BLQ) (see below). PD models
parameters were estimated using the FOCE method
with interaction between interindividual and residual
variabilities. Confidence intervals (CI) of parameter esti-
mates were obtained by nonparametric bootstrap (n =
1000) with stratification by study and dose.
Population pharmacokinetic model
First, the structural PK model was built using both
sparse and rich datasets. One, two and three-compart-
ment models with first-order absorption and elimination
were tested, as well as with saturable (Michaelis-
Menten) elimination. The most appropriate model was
chosen on the basis of the objective function value
(OFV) and simulation-based diagnostics such as normal-
ised predictive discrepancy errors (NPDE) [14]. The
NPDE analysis was performed with BLQ points
excluded.
In the two-compartment model, the parameters were
the elimination clearance (CL/F), the volume of the cen-
tral compartment (Vc/F), the rate constants for transfer
from central to peripheral (kcp) or peripheral to central
compartment (kpc), the rate constant for absorption (ka).
T h eB L Qm e a s u r e m e n t so ft h es p a r s ed a t aw e r e
included in the data and modelled as censored observa-
tions using “method 3” described in [15].
The interindividual variability (IIV) for the PK para-
meters was described using exponential models:
Pi = θ · eηi,w h e r eh is a random variable with normal
distribution, zero mean and variance to be estimated, θ
is a typical value. The IIV was added in a stepwise man-
ner, firstly to clearance and central volume of distribu-
tion. The interindividual random effects were kept in
the model if their inclusion significantly reduced the
OFV and if their relative SE was <50%. A full interindi-
vidual variance-covariance matrix was estimated to
assess if there was any significant covariance in the IIV
structure.
To find the most appropriate residual error model,
additive, proportional and mixed error models were
tested. As data were collected from two quite differently
designed studies, separate residual error models for each
study were tested.
The variables that were investigated for their ability to
e x p l a i nI I Vi nt h eP Ko fH Uw e r eb o d yw e i g h t ,
creatinine, age and sex. Scaling by body weight (for
clearance and central volume of distribution) as
Vc = θV ·
WGT
70 and CL = θCL ·

WGT
70
0.75
,a sw e l la s
CL = θCL + f(covar), f(covar)=
(140 − age) · bodyweight · (1 − coeffsex · sex)
creatinine
(with sex = 0 for men and 1 for women, coeffsex esti-
mated), similar to the Cockroft-Gault formula for creati-
nine clearance [16], were the tested forms of
relationships. The conditions for the variable to be
retained as a covariate were to be biologically plausible,
and to decrease the OFV by at least 5 units, correspond-
ing to a p-value less than 2.5%.
Missing values of body weight were predicted by the
model: if the patient’s weight was known at other time-
point(s), it was predicted by using an interpolated or
adjacent value and an additive individual random effect
whose variance was fixed to the observed intraindividual
v a r i a n c eo ft h eb o d yw e i g h to ft h ed a t a s e t( 1 . 5 ) ;i fn o
data of patient’s weight were available, it was predicted
by using the average weight of the dataset (62 kg for
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dom effect whose variance was fixed to the observed
interindividual variances of the dataset (92 for women,
40 for men).
The time to reach 95% of HU concentration steady-
state was determined by simulation of a typical patient
with 1000 mg dose every day for 6 months.
Population pharmacodynamic models
The PD responses to be described by the model were
HbF percentage and MCV. The observed level of both
these responses depends on the ratio of a production
rate to an elimination rate. Therefore, turnover models
[17] were chosen to fit the data. Models assuming either
stimulation of the production or inhibition of the elimi-
nation of response by HU were tested. The metrics of
HU exposure used as the input into the PD model was
mean drug concentration at steady state, calculated
using the individual posthoc estimates of HU clearance.
Therefore, a sequential modelling approach was used.
The uncertainty in the estimate of clearance was taken
into account by using the IPPSE method [18]. Linear,
Emax, sigmoid and power functions were tested for the
effect of the drug. The final model was chosen on the
basis of the OFV and diagnostic plots, stability and pre-
cision of parameter estimates. IIV and residual error
models were constructed in the same way as for the PK
model.
In addition to demographic variables, baseline mea-
surements of pharmacodynamic variables, as well as
their previous values, rate of change per day from base-
line to the previous value ( V =
Vt−1 − V0
days ), rate of change
per day between the two previous values
( V =
Vt−1 − Vt−2
days ) were investigated as covariates. They
were included as additive or proportional to the drug
effect, production rate or elimination rate. Missing
values were predicted by the model by using the data
average and an individual random effect whose variance
was fixed to the value calculated from the data. The
conditions for covariate inclusion were the same as for
the PK model.
Model evaluation
The quality of models was assessed by goodness-of-fit
plots and simulation-based methods (using 1000 simula-
tions): visual predictive check (VPC) and NPDE. The
mean of prediction error distribution was compared to
zero by a Wilcoxon signed rank test, while its variance
was compared to unity by a Fisher test. For the VPC,
prediction corrections were used so that data of all dose
levels could be used in one plot [19]. BLQ points in the
observed and simulated PK data sets were assigned
values equal to LOQ/2. The VPC plots showed 80% pre-
diction intervals (PI) and medians of the observed and
of the predicted data, as well as 95% confidence areas
around the percentiles. For the PK, a VPC plot in log
scale was also given.
Simulation of alternative dosing regimens
The two simulated dosing regimens were: 1000 mg daily
doses 7 days a week (7/7) and 1000 mg daily doses 5
consecutive days a week (5/7) for the duration of 12
months; 10000 patients were simulated in each arm. For
each covariate, the average observed value was used.
The results were compared graphically by representing
the median profile and the 90% prediction interval of
the HbF% and MCV. In order to determine the steady-
state values of the HbF% and of the MCV and time to
reach 95% of them, such simulations with 7/7 dosing
were extended for 48 months.
Results
Pharmacokinetic data analysis
A summary of PK related patient characteristics is given
in Table 1. In the sparse data, 78% of last doses before
the concentration measurements were 1000 mg, 15%
were 1500 mg, and the rest were 500 mg, 1250 mg or
2000 mg. In the rich dataset, 44% were 1000 mg, 31%
were 1500 mg, and the rest were either 1250 mg or
2000 mg. The median number of measurements per
patient in the sparse dataset was 4 (range: 1 - 9); in the
rich dataset, 10 measurements were available for each
patient.
The PK profiles were best described by a two-com-
partment model (with first-order absorption and elimi-
nation). The NPDE diagnostics indicated that one-
compartment model could not adequately describe these
data. The OFV of the three-compartment model was
not lower than that of the two-compartment model. No
significant nonlinearity in absorption or elimination
could be detected in these data.
Significant interindividual variability was found for Vc,
CL, ka and kcp. Correlations were significant among the
individual values of Vc, CL and kcp. The mixed residual
error model was best for both datasets. The OFVs of PK
models with and without weight-scaling of Vc and CL
(as shown in methods section) were nearly significant,
but this covariate was kept in the model for the sake of
Table 1 Summary of patient characteristics
PKPD dataset Rich PK dataset
Characteristics Median (range) Median (range)
Age 30 (18 - 54) 32 (24 - 52)
Men/women 24/57 5/11
Weight (kg) 60 (45 - 163) 63 (42 - 71)
Creatinine (μM) 65 (27 - 558) 72 (47 - 129)
Urea (μM) 3.1 (0.8 - 10.5) 3.4 (2.4 - 7.7)
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of the model to children (where the effect of weight
would be much more perceptible). The allometric
model for clearance with power 0.75 was better than the
model with power 1 (p = 0.0016).
The final model estimates are given in Table 2. As the
bioavailability was not estimated here, the reported esti-
mates for CL and Vc represent apparent pharmacoki-
netic parameters CL/F and Vc/F. Their values in Table 2
are given for a patient of 70 kg weight, which is the
scaling base. To obtain values for patients of different
weight, the population value should be multiplied by
weight/70 for Vc and by (weight/70)
0.75 for CL. The esti-
mate of the rate constant of transfer from the peripheral
to the central compartment (kpc) was very small and
unstable, so its value was fixed to 0.004 (h
-1)( i t sb e s t
estimate) and this resulted in lower estimate of IIV of
kcp and better stability of the model. With this model,
the time to reach 95% of the steady-state was typically
about 35 days.
Simulation-based diagnostics VPC (Figure 1) and
NPDE indicated that the model adequately described
the measured data. The mean of normalized prediction
errors was significantly different from zero (mean =
0.12, p = 0.016), but translated into HU concentrations,
the mean difference between observed and predicted
concentrations was only 0.08 mg/L. This difference was
not considered as relevant from a clinical point of view.
The variance of normalized prediction errors was not
significantly different from unity (0.893, p = 0.12).
Pharmacodynamic data analysis
The median number of HbF% measurements per patient
was 5 (range: 1 - 10); the total number of patients and
measurements was 77 and 391 respectively. The median
number of MCV measurements per patient was 6
(range: 3 - 10); the total number of patients and mea-
surements was 80 and 439 respectively. 43% of patients
with HbF% measurements and 49% of patients with
MCV measurements were followed for 6 months (med-
i a n( r a n g e )f o rH b F % :6m o n t h s( 9d a y s-3 0m o n t h s ) ;
for MCV: 6 months (1 - 30 months)). Summary statis-
tics of the pharmacodynamic variables at the beginning
a n da f t e r6m o n t h si nt h es t u d ya r eg i v e ni nT a b l e3 .
The treatment with HU induced an increase in HbF, its
percentage (Figure 2 shows its maximums) and in MCV,
as well as decreases in bilirubin and LDH, which were
indicative of decrease in the rate of hemolysis. Decreases
in neutrophils (PMN) and platelets were mild, not
reaching below normal levels.
Population PD model of the percentage of fetal hemoglobin
The turnover model with inhibition of the elimination
rate was found to describe best the HbF% data. However,
in this dataset, no relationship between HU concentra-
tion and HbF% could be identified, because all patients
were estimated to have the maximum drug effect. The
rate of change per day between the two last MCV obser-
vations (ΔMCV) was found to be a significant covariate
for the production rate, Kin (p < 0.00001). The median
(range) ΔMCV was 0.16 (-0.27 to 0.87). The final model
was (cf. parameter estimates in Table 4):
dHbF%
dt
= Kin,i − Kout,i ·

1 − Imax,i

· HbF%
where Kin,i = Kin,TV · eηKin,i · eθ MCV· MCV, Kout,i = Kout,TV · eηKout,i,
Imax,i =
eLImax,TV+ηImax,i
1+eLImax,TV+ηImax,i and LImax is the logit-transformed
Imax.
Table 2 Parameter estimates of the population PK model
Parameters Typical values (95% CI) Standard deviations of IIV (95% CI) Interindividual CV
Vc/F (L) (for a patient of 70 kg) 45.3 (38.9 - 50.5) 0.34 (0.23 - 0.46) 35%
Cl/F (L/h) (for a patient of 70 kg) 11.6 (10.4 - 12.9) 0.29 (0.22 - 0.40) 30%
ka (h
-1) 3.29
θka (h
-1)( ka = θka · eηka + α) 3.02 (2.25 - 4.19) 1.34 (1.16 - 1.65) 224%
kcp (h
-1) 0.027 (0.021 - 0.037) 0.57 (0.43 - 0.95) 62%
kpc (h
-1) (fixed) 0.004 - -
SD of the additive component of the residual error (mg/L)
- for densely sampled data 0.319 (0.197 - 0.492)
- for sparsely sampled data 0.353 (0.257 - 0.522)
SD of the proportional component of the residual error
- for densely sampled data 0.12 (0.083 - 0.154)
- for sparsely sampled data 0.435 (0.349 - 0.506)
Correlation (hVc, hCl) 0.71
Correlation (hVc, hkcp) -0.26
Correlation (hCL, hkcp) 0.37
CI: confidence intervals, obtained by bootstrap (n = 1000), IIV: interindividual variability, CV: the apparent coefficient of variation of interindividual variability.
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Kout and LImax, with correlation between Kout and LImax.
A proportional residual error model was selected.
Simulation-based diagnostics VPC (Figure 3) and
NPDE indicated that the model adequately described
the observed HbF% data. The mean of NPDE was 0.03
(p = 0.3), the variance was 0.937 (p = 0.38). Concerning
the VPC, for the first 300 days, the difference between
the medians of HbF% observations and of its predictions
was approximately 2%, which was not clinically signifi-
cant. Only 14 patients out of 81 continued the treat-
ment longer than 300 days, therefore the percentiles at
later times may be imprecise. The NPDE versus time
plots did not indicate any prediction deficiencies (data
not shown).
In the simulation, median HbF% at steady-state was
about 18.6%, 95% of it was reached in about 26 months.
Population PD model of the mean corpuscular volume
The turnover model with inhibition of the elimination
rate was found to describe best the MCV data. The inhi-
bition was best described by a power function of average
concentration. The rate of change per day between the
two last HbF% observations (ΔHbF%) was found to be a
significant covariate on the parameter b (p < 0.00001).
Figure 1 PC-VPC for HU concentrations. The lines show the 10
th,5 0
th and 90
th percentiles of observed data (thick lines) and of predictions
(thin lines); the grey areas represent the 95% confidence areas around the percentiles. PC-VPC: prediction-corrected visual predictive check. Left
panel: linear scale, right panel: log scale.
Table 3 Summary statistics of PD variables
PD variables At baseline
Median (range)
Number of patients After 6 months of treatment
Median (range)
Number of patients
HbF% 6.3 (0.6 - 30.7) 65 15.7 (3.9 - 41.6) 46
HbF (g/dL) 0.48 (0.04 - 2.7) 63 1.59 (0.34 - 4.04) 46
Hemoglobin (g/dL) 8.8 (6.3 - 11.9) 73 9.6 (6.9 - 14.4) 55
MCV (fL) 90 (68 - 113) 74 111 (81 - 131) 55
MCH (pg) 30 (21 - 36) 73 37 (25 - 44) 55
PMN (10
9/L) 56 (25 - 80) 71 49 (26 - 86) 53
Platelets (10
9/L) 428 (122 - 995) 74 316 (109 - 528) 55
Bilirubin (μM) 43 (9 - 96) 75 30 (6 - 113) 53
LDH (UI/L) 355 (155 - 800) 73 317 (168 - 766) 52
Ferritin (μg/L) 346 (16 - 4500) 72 275 (14 - 2940) 52
AST (UI/L) 32 (17 - 79) 75 31 (12 - 81) 53
ALT (UI/L) 22 (7 - 84) 75 21 (7 - 83) 53
Creatinine (μM) 65 (38 - 142) 75 64 (35 - 137) 52
Urea (μM) 2.9 (1.2 - 13.3) 75 3.3 (1.5 - 9) 52
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The final model was (cf. parameter estimates in Table 5):
dMCV
dt
= Kin,i − Kout,i ·

1 − βi · Concγ
· MCV
where Kin,i = Kin,TV · eηKin,i, Kout,i = Kout,TV · eηKout,i,
βi = βTV · eηβ,i+θ· HbF%
Significant interindividual variability was found for Kin,
Kout and b, with correlations between all three para-
meters. A proportional residual error model was
selected.
Simulation-based diagnostics VPC (Figure 4) and
NPDE indicated that the model adequately described
the observed MCV data. The mean of NPDE was -0.02
(p = 0.87), the variance was 0.9 (p = 0.15). In the VPC,
the difference between the medians of MCV observa-
tions and of its predictions was approximately 5 fL,
which was not clinically significant. In the simulation,
median MCV level at steady-state was about 104 pL,
95% of it was reached in about 90 days.
Simulation of alternative dosing regimens
The simulated HbF% and MCV profiles with the two
dosing regimens are shown in Figures 5 and 6 respec-
tively. For MCV, the difference was very small. For HbF
%, continuous dosing led to more significantly stronger
response, especially for patients reaching the highest
levels of HbF%. It can be observed that HbF% required
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Figure 2 Maximum achieved HbF% and corresponding cumulative number of patients.
Table 4 Parameter estimates of the population HbF% model
Parameters Typical values (95% CI) SD of IIV (95% CI) Interindividual CV
Kin (%/day) 0.071 (0.055 - 0.094) 0.585 (0.472 - 0.681) 63%
Kout (day
-1) 0.013 (0.010 - 0.019) 0.486 (0.334 - 0.602) 52%
LImax (unitless) 0.276 (-0.081 - 0.644)
(Imax = 0.569 (0.48 - 0.656))
1.44 (1.07 - 1.97) 27%
θΔMCV (day
-1) 1.37 (0.95 - 1.76)
SD of proportional residual error 0.142 (0.119 - 0.162)
Correlation (hKout, hImax) 0.892
CI: confidence intervals, obtained by bootstrap (n = 1000), SD: standard deviation, IIV: interindividual variability, CV: the apparent coefficient of variation of
interindividual variability.
Paule et al. Orphanet Journal of Rare Diseases 2011, 6:30
http://www.ojrd.com/content/6/1/30
Page 7 of 12a much longer time than MCV to reach the steady-state
(approximately 26 and 3 months for 95% of steady-state
levels respectively). The inter-individual variability of
steady-state of HbF% was higher than that of MCV: the
ratios of the 95
th to the 5
th percentile were approxi-
mately 10 and 1.5 respectively.
Discussion
In this study, population PK-PD models were developed
for the first time, in order to characterize the exposure-
efficacy relationships of HU and its variability.
The pharmacokinetics of HU was found to be linear.
Other studies in rats and in humans using doses ran-
ging between 10 to 800 mg/kg in patients with malig-
nancies identified parallel linear renal and saturable
non-renal elimination [20]. The latter could not be
detected in the studies reported here, probably because
the doses administered were not high enough to reach
saturation of non-renal elimination pathways (10 to 35
mg/kg per os in SCA). Otherwise, the presented model
was consistent with the results of previously reported
studies.
Figure 3 PC-VPC for HbF%. The lines show the10
th,5 0
th and 90
th percentiles of observed data (thick lines) and of predictions (thin lines); the
grey areas represent the 95% confidence areas around the percentiles. PC-VPC: prediction-corrected visual predictive check.
Table 5 Parameter estimates of the population MCV model
Parameters Typical values (95% CI) SD of IIV (95% CI) Interindividual CV
Kin (%/day) 3.71 (3.13 - 4.30) 0.191 (0.083 - 0.401) 19%
Kout (day
-1) 0.042 (0.035 - 0.048) 0.186 (0.044 - 0.415) 19%
b (L. mg
-1)
1/g 0.099 (0.064 - 0.135) 0.457 (0.336 - 0.599) 48%
g (unitless) 0.19 (0.02 - 0.46)
θΔHbF% (day
-1) 1.22 (-0.07 - 2.21)
SD of proportional residual error 0.036 (0.030 - 0.040)
Correlation (hKin, hKout) 0.87
Correlation (hKin, hb) -0.98
Correlation (hKout, hb) -0.95
CI: confidence intervals, obtained by bootstrap (n = 1000), SD: standard deviation, IIV: interindividual variability, CV: the apparent coefficient of variation of
interindividual variability.
Paule et al. Orphanet Journal of Rare Diseases 2011, 6:30
http://www.ojrd.com/content/6/1/30
Page 8 of 12Figure 4 PC-VPC for MCV. The lines show the 10
th,5 0
th and 90
th percentiles of observed data (thick lines) and of predictions (thin lines); the
grey areas represent the 95% confidence areas around the percentiles. PC-VPC: prediction-corrected visual predictive check.
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Figure 5 Profiles of simulated HbF% with two dosing regimens. 90% prediction intervals and medians of simulated HbF% with HU 7/7
(solid lines) and 5/7 (dotted lines) (n = 10000).
Paule et al. Orphanet Journal of Rare Diseases 2011, 6:30
http://www.ojrd.com/content/6/1/30
Page 9 of 12For a given dosing regimen, HU exposure varied
approximately fivefold among patients. Part of the varia-
bility of apparent clearance and apparent volume of the
central compartment was related to body weight. Clear-
ance was better correlated with body weight at a 0.75
power, according to allometric scaling laws [21]. Because
the maintenance dose of a drug to reach a desired aver-
age concentration is determined solely by its clearance,
this allometric relationship implies that the HU dosing
rate should be calculated with respect to body weight to
the power of 0.75, or equivalently, to free fatty mass
[22], in order to decrease the interindividual variability
in HU exposure. Finally, the time to reach 95% of the
pharmacokinetic steady-state was typically 35 days, in
contrast with the delay to reach the maximal effect of
HU, as discussed below.
The haematological results obtained in this study are
compatible with those previously reported [23]. Our
study brought further insight on the relationship
between exposure and efficacy.
First, from a kinetic point of view, if we expressed the
estimated Kout parameters as half-lives and then multi-
plied them by 5 to obtain approximate times to reach
steady-state before the drugi st a k e n ,w ec o u l ds e et h a t
they are around 265 and 83 days for HbF% and MCV
respectively. HU is assumed to reduce Kout and
therefore extend this time to steady-state. The simula-
tions under a constant dosing rate at 1000 mg per day
show that 95% of the steady-state levels of HbF% and
MCV need 26 months and 3 months to be reached,
respectively. If the dosing regimen is modified, the same
delay is required to reach a new steady-state. Hence, the
variation of MCV is more rapid than that of HbF%. The
3 month delay for MCV is certainly related to the life
span of RBC of 120 days and corresponds to the time
needed to renew three quarters of RBCs.
Second, the effect of HU on HbF% was estimated to
be at its maximum independently of the exposure, in
the dose range of our study (500 to 2000 mg/day). How-
ever, the intensity of the effect (Imax)v a r i e da m o n g
patients, with a typical value of 0.57 and a coefficient of
variation of 27%. None of the demographic and biologi-
cal indices was correlated with these variations. Part of
this variability might be explained by genetic poly-
morphisms in genes regulating HU metabolism or trans-
porters, HbF expression and erythroid progenitor
proliferation [8-10]. These polymorphisms might modu-
late the patient response to HU. In addition, the HU-
inducible small guanosine triphosphate-binding protein,
secretion-associated and RAS-related (SAR) protein has
been demonstrated to play a key role in HBG induction
and erythroid maturation by causing cell apoptosis and
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Figure 6 Profiles of simulated MCV with two dosing regimens. 90% prediction intervals and medians of simulated MCV with HU 7/7 (solid
lines) and 5/7 (dotted lines) (n = 10000).
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related to this pathway have been described such as
sar1a promoter polymorphisms [10] and may also con-
tribute to variability. Finally, patient compliance to treat-
ment might also be a source of variability in response,
but no information on compliance was available in this
study.
Third, HU increased HbF% by reducing HbF elimina-
tion rate constant by 57% (for a typical patient). Abso-
lute values of HbF per RBC (medians) at baseline and
after 6 months were 1.9 pg and 5.6 pg respectively,
which confirms that HU leads to a real increase in HbF
per cell. Theoretically, a full inhibitor could reduce the
elimination rate further, leading to a higher increase of
HbF%. Hence, there is room for improvement, e.g. by
looking for stronger inhibitors, or combining HU with
other drugs to be discovered.
Fourth, a relation between HU exposure and effect on
MCV could be identified, but this relation was flat as in
t h es t u d i e dr a n g eo fd r u ge x p o s u r et h ee f f e c tw a sc l o s e
to its maximum. When the average HU concentration
was 2 or 9 mg/L (the extremes of this study), the MCV
decay rate constant (Kout) was multiplied by 0.88 or 0.84
respectively, with an interindividual coefficient of varia-
tion of 49%. Hence the inhibition of MCV “elimination”
by HU was less potent than that of HbF, and the inter-
individual variability was greater.
Regarding simulations, a close inspection of Figures 5
and 6 reveals that the interindividual variability of the
steady-state values of HbF% and MCV are different, the
ratio of the 95
th to 5
th percentile being approximately
10 and 1.5 respectively. Although the effects of HU on
MCV and HbF% variations are correlated, the steady-
state value of MCV at month 3 is not predictive of the
HbF% value at month 26. Hence, HbF% level, which is
also directly related to the relief of sickle cell disease
symptoms, may be the best biomarker for monitoring
HU treatment.
No dose-limiting toxicity occurred in this study, which
prevented a toxicity model from being developed.
Nevertheless, cytopenia may occur during HU treat-
ment, leading to dose reduction. We compared by simu-
lation two dosing regimens, one continuous daily and
the other with interruptions of 2 days after every 5 days.
The difference was very small regarding the MCV pro-
file, but larger for the HbF% profile, particularly for
simulated patients in the last quartile of HbF% distribu-
tion. For these patients, continuous dosing may induce a
clinically relevant increase of HbF% compared with the
discontinuous schedule. The limits of this simulation
exercise are that genetic polymorphisms were not
accounted for, and some other biomarkers (arginase,
NO enzymes, activated adhesion molecules, phosphati-
dylserine externalization [25,26]) were not evaluated.
Conclusions
The mode of action of HU on two clinically relevant
biomarkers of its efficacy was established. The high
variability of response to HU was related in part to
pharmacokinetics (HU exposure varied approximately
fivefold among patients), and to pharmacodynamics.
The steady-state of HbF% and MCV levels need 26
months and 3 months to be reached, respectively, and
the interindividual variability of the steady-state values
of HbF% is much greater than that of MCV. As a result,
the steady-state value of MCV at month 3 is not predic-
tive of the HbF% value at month 26. Hence, HbF% level
may be a better biomarker than MCV for monitoring
HU treatment. Simulations showed that continuous dos-
ing led to a stronger response than intermittent dosing
(5 days out of 7), especially for patients reaching the
highest levels of HbF%. Hence, a continuous dosing
should be prescribed. Finally, an exciting perspective
suggested by the model is that HbF could be further
increased by more potent drugs or by drug combina-
tions. In future studies, the model may allow to describe
quantitatively the impact of relevant polymorphisms on
the variability of response to HU, in order to refine the
simulations and to yield specific recommendations for
each genotype or haplotype.
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